Acadia Pharmaceuticals(ACAD)
SAN DIEGO, CA
Pharmaceutical1 H-1B visas (FY2023)Focus: Small Molecules
Acadia Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (3)
1 discontinued product not shown
DAYBUE
trofinetide
Peak
PeptideORAL · SOLUTION
Cytochrome P450 3A4 Inhibitors
Rett syndrome in adultsolder
2023
0
DAYBUE STIX
trofinetide
Launch
PeptideORAL · FOR SOLUTION
Cytochrome P450 3A4 Inhibitors
Rett syndrome in adultsolder
2025
0
NUPLAZID
pimavanserin tartrate
Peak
ORAL · CAPSULE
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
hallucinationsdelusions associated with Parkinson's disease psychosis
2018
0
Pipeline & Clinical Trials
Real-world, non-interventional
Parkinson Disease PsychosisClinical Trials (1)
NCT03152292The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
N/APimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT02762591Expanded Access of Pimavanserin for Patients With PD Psychosis
N/AObservation of minor phenomena
Parkinson DiseaseClinical Trials (1)
NCT05240339Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
N/ASupport program
Knee ArthropathyClinical Trials (1)
NCT06575621Knee-hip Surgery Wait-list Support Program
N/AVirtual reality guided motor rehabilitation
Stroke AcuteClinical Trials (1)
NCT06864741Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.
N/AACP-104
SchizophreniaClinical Trials (1)
NCT00628420Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
Phase 1Pimavanserin
Parkinson DiseaseClinical Trials (1)
NCT05796167Pimavanserin for Sleep in Parkinson Disease
Phase 1ACP-204
Lewy Body Dementia PsychosisClinical Trials (1)
NCT07029581Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Phase 2Phase 2
Clinical Trials (1)
NCT03018340Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Phase 2Pimavanserin 34 mg
Intermittent Explosive DisorderClinical Trials (1)
NCT05895513Pimavanserin and Aggression and Social Cognition.
Phase 2Pimavanserin
SchizophreniaClinical Trials (1)
NCT02970305Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Phase 2Pimavanserin
Agitation and Aggression in Alzheimer's DiseaseClinical Trials (1)
NCT03118947A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Phase 2ACP-103
SchizophreniaClinical Trials (1)
NCT00361166Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Phase 2Active drug: pimavanserin 17mg
Parkinson DiseaseClinical Trials (1)
NCT03947216Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
Phase 2ACP-044 Dose A
Acute Postoperative PainClinical Trials (1)
NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy
Phase 2ACP-104
SchizophreniaClinical Trials (1)
NCT00490516ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Phase 2Pimavanserin 34 milligrams
SchizophreniaClinical Trials (1)
NCT03994965The Sub-Sero Study
Phase 2Pimavanserin 34 mg
Agitation and Aggression in Alzheimer's DiseaseClinical Trials (1)
NCT02992132Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
Phase 2ACP-103
HallucinationsClinical Trials (1)
NCT00087542Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
Phase 2Pimavanserin tartrate
Alzheimer's Disease PsychosisClinical Trials (1)
NCT02035553A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Phase 2pimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT01518309An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Phase 2Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Autism Spectrum DisorderClinical Trials (1)
NCT05999240Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
Phase 2Pimavanserin
Parkinson's DiseaseClinical Trials (1)
NCT04164758Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Phase 2Phase 2
Clinical Trials (1)
NCT07284667ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Phase 2Probiotics
AnxietyClinical Trials (1)
NCT02035878Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression
Phase 2ACP-044 Dose A
Osteoarthritis PainClinical Trials (1)
NCT05008835Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
Phase 2Phase 2
Clinical Trials (1)
NCT03482882Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
Phase 2Phase 2/3
Clinical Trials (1)
NCT05555615Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Phase 2/3Trofinetide
Rett SyndromeClinical Trials (1)
NCT04988867An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Phase 2/3Phase 2/3
Clinical Trials (1)
NCT06159673ACP-204 in Adults With Alzheimer's Disease Psychosis
Phase 2/3Phase 2/3
Clinical Trials (1)
NCT05523895Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Phase 2/3Trofinetide
Rett SyndromeClinical Trials (1)
NCT04181723Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Phase 3Trofinetide
Rett SyndromeClinical Trials (1)
NCT04279314Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Phase 3ACP-204
Lewy Body Dementia PsychosisClinical Trials (1)
NCT07095465Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Phase 3Pimavanserin
SchizophreniaClinical Trials (1)
NCT02970292Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Phase 3Phase 3
Clinical Trials (1)
NCT06194799ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Phase 3Phase 3
Clinical Trials (1)
NCT03968159Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Phase 3Pimavanserin
SchizophreniaClinical Trials (1)
NCT03121586Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Phase 3Placebo
Dementia-related PsychosisClinical Trials (1)
NCT03325556Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Phase 3Pimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT00550238A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3Phase 3
Clinical Trials (1)
NCT03623321Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Phase 3Phase 3
Clinical Trials (1)
NCT04000009Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Phase 3pimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT01174004A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Phase 3Carbetocin
Hyperphagia in Prader-Willi SyndromeClinical Trials (1)
NCT06420297OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Phase 3Carbetocin
Hyperphagia in Prader-Willi SyndromeClinical Trials (1)
NCT06173531Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Phase 3Phase 3
Clinical Trials (1)
NCT03575052A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Phase 3Pimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT00477672A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3Pimavanserin
SchizophreniaClinical Trials (1)
NCT04531982Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Phase 3trofinetide
Rett SyndromeClinical Trials (1)
NCT04776746Open-Label Extension Study of Trofinetide for Rett Syndrome
Phase 3Pimavanserin tartrate
Parkinson's Disease PsychosisClinical Trials (1)
NCT00658567A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 4 approved products, 54 clinical trials
Top TAs: Neurology
H-1B (2023): 1 approval
SEC Filings: 2 available
Portfolio Health
Launch1 (25%)
Peak3 (75%)
4 total products
Financials (FY2025)
Revenue
$726M40%
R&D Spend
$352M(48%)3%
Net Income
-$61MCash
$189MVisa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub